Hantavirus infections are widely distributed across Europe, with the exception of some Mediterranean countries which reported a very low number of cases.
Immunisation is the only effective method of prevention. Mumps vaccine is given in the form of the combined trivalent measles-mumps-rubella (MMR) vaccine in all European countries with a first dose at or before 18 months of age. The timing of the second dose varies across countries.
ECDC promotes the performance of external quality assessment (EQA) schemes, in which laboratories are sent simulated clinical specimens or bacterial isolates for testing by routine or reference laboratory methods. EQA schemes, or laboratory proficiency testing, provide information about the accuracy of different characterisation and typing methods as well as antimicrobial susceptibility testing (AST) and the sensitivity of the methods in place to detect a certain pathogen or novel resistance patterns.
The online database of the ECDC HAI-Net point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use provides European reference data on HAIs and antimicrobial use in acute care hospitals in Europe. See the PPS reports on antimicrobial use by indication and specialty